

ASX ANNOUNCEMENT

Placement to Raise up to \$3.83 million

23 April 2021, Brisbane, Australia

Analytica Ltd (ASX:ALT, **Company**) developer of the Enhanced Infusion System and manufacturer of the PeriCoach® System are pleased to announce a share placement at an issue price of 0.35 cents per share which will raise up to \$3.83 million subject to shareholder approval (**Placement**).

This capital will allow Analytica to pursue opportunities for both PeriCoach and EIS in foreign and domestic markets, particularly North America and Europe, adding to the existing manufacturing and distribution agreements announced for China and the Middle East.

Subject to shareholder approval, under the Placement:

- up to 1,094,188,797 new shares (**New Shares**) will be issued to institutional and sophisticated investors and other persons to whom no disclosure is required under the Corporations Act 2001 (Cth); and
- subscribers will also receive 1 new attaching option for each New Share subscribed for, exercisable at 0.5 cents with an expiry date of 18 June 2023 (**Attaching Options**). The Company intends to apply for the grant of quotation of the Attaching Options subject to being able to satisfy the conditions of quotation.

The Placement will occur in two tranches.

In the first tranche, 879,903,083 New Shares will be issued to raise approximately \$3.08 million cash before costs. These shares will be issued under the Company's placement capacity under LR 7.1 and enhanced placement capacity under LR 7.1A. Accordingly, shareholder approval is not required and will not be sought for the issue of these shares. Completion of the first tranche is expected to occur on 29 April 2021.

The second tranche of New Shares comprises the proposed issue, subject to shareholder approval, of:

- 214,285,714 New Shares to convert \$750,000 of a loan owing to a lender associated with Analytica Chairman, Dr Monsour. Shareholder approval for these shares will be sought for the purposes of Listing Rules 7.1 and 10.11. No new cash will be raised by this share issue;
- up to 1,094,188,797 Attaching Options. Shareholder approval for these Attaching Options will be sought under Listing Rules 7.1 and 10.11 (for participation by Dr Monsour).

180 Markets Pty Ltd acted as sole lead manager to the Placement and, subject to shareholder approval, will receive 25,000,000 options exercisable at 0.5 cents with an expiry date of 18 June 2023 (**Broker Options**). Shareholder approval will be sought at the same meeting to consider the issue of securities under the second tranche of the Placement.

The Company expects to hold an extraordinary general meeting to seek the necessary shareholder approvals on or about 18 June 2021.

This notice has been authorised for release to the ASX by the Board of the Company.



For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

About Analytica Limited

Analytica is a product development and commercialisation company, based in Queensland, Australia, focussed on Class I and II medical device products.

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia and has CE mark and USFDA 510(k) clearance for the treatment of urinary incontinence.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of mild to moderate pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

Analytica is also the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.

